Tanya Green
About Tanya Green
Tanya Green is Chief Development Officer at Bicara Therapeutics (BCAX), appointed as part of a management expansion highlighted in BCAX’s Q3 2025 business update . She brings 20+ years of leadership in global drug development and regulatory affairs, previously serving as SVP & Chief of Staff and earlier VP, Global Regulatory Sciences at Blueprint Medicines, with prior regulatory roles at Alexion and Synageva and an early career at Sanofi Genzyme; she holds a BS in Biology (Suffolk University) and an MS in Regulatory Affairs & Health Policy (Massachusetts College of Pharmacy and Health Sciences) . BCAX is an emerging growth company and is not required to provide pay-versus-performance or say‑on‑pay disclosures at this time . Her appointment coincided with key corporate milestones, including FDA Breakthrough Therapy Designation for ficerafusp alfa plus pembrolizumab in first-line HPV-negative HNSCC .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Blueprint Medicines | Senior Vice President & Chief of Staff | — | Led enterprise strategy and cross-functional initiatives across clinical, regulatory, and program development |
| Blueprint Medicines | Vice President, Global Regulatory Sciences | — | Directed regulatory strategy, CMC, and health-authority interactions for global portfolio |
| Alexion Pharmaceuticals | Regulatory leadership roles | — | Advanced regulatory pathways for rare disease assets |
| Synageva BioPharma | Regulatory leadership roles | — | Built regulatory capabilities through growth and acquisition cycles |
| Sanofi Genzyme | Early career | — | Foundations in large-cap biopharma regulatory operations |
External Roles
No public company directorships or committee roles are disclosed in BCAX filings or Equilar’s executive bio for Tanya Green .
Fixed Compensation
- Compensation details for Tanya Green are not disclosed in the 2025 DEF 14A, which covers 2024 named executive officers (CEO, President/COO, CFO) and director pay; she is not listed among NEOs for 2024 .
- Executive officers listed as of April 14, 2025 do not include a Chief Development Officer, consistent with her appointment later in 2025 .
Performance Compensation
- No individual incentive targets, performance weightings, or payouts are disclosed for Tanya Green to date in BCAX filings .
- Company policies governing equity award timing and granting practices are described (no timing around MNPI; regular schedules), but these are not individualized to Green .
Equity Ownership & Alignment
- Tanya Green does not appear among principal stockholders or the individual beneficial ownership table as of April 14, 2025 (≥5% holders and directors/NEOs listed) .
- Alignment and trading policies: BCAX prohibits derivative transactions and has a Rule 10b5‑1 plan policy for pre‑programmed trading; the insider trading policy highlights risks of margin accounts/pledging and outlines compliance expectations . BCAX maintains a clawback policy requiring recovery of incentive-based compensation after certain restatements, applicable to current/former executive officers .
Employment Terms
- Individual employment agreement terms for Tanya Green are not disclosed in current filings .
- For context only (not specific to Green): BCAX’s Second Amended Employment Agreements for NEOs provide severance for qualifying terminations (12 months base salary continuation and COBRA outside change-in-control), and lump-sum plus COBRA and accelerated vesting for time-based awards in certain change-in-control scenarios, with enhanced multiples for specified transactions for CEO/President; excise tax cutback applies . These terms may differ for non‑NEO executives.
Investment Implications
- New CDO hire with deep development/regulatory pedigree supports execution of pivotal and expansion cohorts and scale-up of clinical operations; appointment was explicitly cited in corporate highlights in Q3 2025 .
- Lack of disclosed individual compensation/ownership limits immediate assessment of pay-for-performance alignment or insider selling pressure; monitor future Item 5.02 8‑K and 2026 proxy for base salary, bonus targets, equity grants, vesting schedules, and ownership .
- Governance features (clawback; insider trading and 10b5‑1 policies) reduce misalignment and headline risk, but individual adherence and any future 10b5-1 plan adoption by Green will be a key signal for trading patterns .
- Corporate execution momentum (BTD for lead asset; ongoing pivotal trial) provides a constructive backdrop; Green’s regulatory and development experience at Blueprint/Alexion/Synageva should be additive to BCAX’s late-stage strategy .